Literature DB >> 16473439

Excitotoxic mechanisms and the role of astrocytic glutamate transporters in traumatic brain injury.

Jae-Hyuk Yi1, Alan S Hazell.   

Abstract

Glutamate excitotoxicity plays an important role in the development of secondary injuries that occur following traumatic brain injury (TBI), and contributes significantly to expansion of the total volume of injury. Acute increases in extracellular glutamate levels have been detected in both experimental brain trauma models and in human patients, and can lead to over-stimulation of glutamate receptors, resulting in a cascade of excitotoxic-related mechanisms culminating in neuronal damage. These elevated levels of glutamate can be effectively controlled by the astrocytic glutamate transporters GLAST (EAAT1) and GLT-1 (EAAT2). However, evidence indicate these transporters and splice variant are downregulated shortly following the insult, which then precipitates glutamate-mediated excitotoxic conditions. Lack of success with glutamate receptor antagonists as a potential source of clinical intervention treatment following TBI has resulted in the necessity for a better understanding of the mechanisms that underlie the process of excitotoxicity, including the function and regulation of glutamate transporters. Such new insight should improve the likelihood of development of novel avenues for therapeutic intervention following TBI.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16473439     DOI: 10.1016/j.neuint.2005.12.001

Source DB:  PubMed          Journal:  Neurochem Int        ISSN: 0197-0186            Impact factor:   3.921


  162 in total

1.  Hypersensitive glutamate signaling correlates with the development of late-onset behavioral morbidity in diffuse brain-injured circuitry.

Authors:  Theresa Currier Thomas; Jason M Hinzman; Greg A Gerhardt; Jonathan Lifshitz
Journal:  J Neurotrauma       Date:  2011-12-01       Impact factor: 5.269

2.  Effect of exposure to 1,800 MHz electromagnetic fields on heat shock proteins and glial cells in the brain of developing rats.

Authors:  Aurélie Watilliaux; Jean-Marc Edeline; Philippe Lévêque; Thérèse M Jay; Michel Mallat
Journal:  Neurotox Res       Date:  2010-11-02       Impact factor: 3.911

Review 3.  Fluorine-18 patents (2009-2015). Part 1: novel radiotracers.

Authors:  Allen F Brooks; Lindsey R Drake; Megan N Stewart; Brian P Cary; Isaac M Jackson; Dale Mallette; Andrew V Mossine; Peter J H Scott
Journal:  Pharm Pat Anal       Date:  2015-12-16

4.  Neuroprotective effects by nimodipine treatment in the experimental global ischemic rat model : real time estimation of glutamate.

Authors:  Seok Keun Choi; Gi-Ja Lee; Samjin Choi; Youn Jung Kim; Hun-Kuk Park; Bong Jin Park
Journal:  J Korean Neurosurg Soc       Date:  2011-01-31

Review 5.  Transporters at CNS barrier sites: obstacles or opportunities for drug delivery?

Authors:  Lucy Sanchez-Covarrubias; Lauren M Slosky; Brandon J Thompson; Thomas P Davis; Patrick T Ronaldson
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

6.  Establishing a Clinically Relevant Large Animal Model Platform for TBI Therapy Development: Using Cyclosporin A as a Case Study.

Authors:  Susan S Margulies; Todd Kilbaugh; Sarah Sullivan; Colin Smith; Kathleen Propert; Melissa Byro; Kristen Saliga; Beth A Costine; Ann-Christine Duhaime
Journal:  Brain Pathol       Date:  2015-05       Impact factor: 6.508

Review 7.  Traumatic brain injury: can the consequences be stopped?

Authors:  Eugene Park; Joshua D Bell; Andrew J Baker
Journal:  CMAJ       Date:  2008-04-22       Impact factor: 8.262

8.  Reduction in expression of the astrocyte glutamate transporter, GLT1, worsens functional and histological outcomes following traumatic spinal cord injury.

Authors:  Angelo C Lepore; John O'Donnell; Andrew S Kim; Eun Ju Yang; Alisha Tuteja; Amanda Haidet-Phillips; Colin P O'Banion; Nicholas J Maragakis
Journal:  Glia       Date:  2011-08-31       Impact factor: 7.452

9.  Niflumic acid, a TRPV1 channel modulator, ameliorates stavudine-induced neuropathic pain.

Authors:  Lovish Marwaha; Yashika Bansal; Raghunath Singh; Priyanka Saroj; Rupinder Kaur Sodhi; Anurag Kuhad
Journal:  Inflammopharmacology       Date:  2016-10-18       Impact factor: 4.473

10.  Reduced early hypoxic/ischemic brain damage is associated with increased GLT-1 levels in mice expressing mutant (P301L) human tau.

Authors:  Guanghong Liao; Miou Zhou; Simon Cheung; James Galeano; Nam Nguyen; Michel Baudry; Xiaoning Bi
Journal:  Brain Res       Date:  2008-11-01       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.